Answer
Rifampicin (rifampin) 600 mg once daily, a strong CYP3A4 inducer, decreased pemigatinib geometric mean AUC by 85% (90% CI: 84%–86%), potentially reducing pemigatinib efficacy.
Sources for this answer
- Pemazyre 4.5 mg - tabletsIncyte Biosciences UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 5Document updated
Sources checked